Jamie P. Dwyer
( out of 59 reviews )

Jamie P. Dwyer, MD

Languages spoken: English

Clinical Locations

Kidney & Liver Clinic

Kidney and Liver Clinic
Salt Lake City
801-581-2772
Directions

  • Jamie P. Dwyer, M. D. is Assistant Vice-President for Clinical Research at the University of Utah Health in Salt Lake City, UT, USA. He is Professor of Medicine in the Division of Nephrology & Hypertension, and Director of the Utah Data Coordinating Center and the Clinical Research Support Office. He is current Principal Investigator of the Collaborative Study Group (CSG), an international academic research organization dedicated to the exceptionally rigorous design, conduct, analysis, and reporting of large, multi-center clinical trials. He has served on multiple Executive and Steering committees for large trials, particularly in CKD progression and cardiovascular outcomes. In 2015, Dr. Dwyer was appointed as a Consultant to the USA’s Food and Drug Administration’s (FDA) CardioRenal Advisory Committee, and has both served on and defended data before FDA Advisory Committees. In 2017, he and colleagues founded Innovative Renal Care, a health services delivery company dedicated to improving the care of dialysis patients in the United States. In 2023, he and colleagues founded Corventum, Inc.

    Dr. Dwyer is a practicing clinical nephrologist who sees patients across the spectrum of kidney disease. He is an accomplished and highly lauded educator, receiving numerous teaching awards, culminating in his election to Vanderbilt’s Academy for Excellence in Education while faculty there in 2013.

    Dr. Dwyer holds an Sc. B degree in Mathematics and Latin from Brown University in 1996, and an M. D. with Distinction from Brown University Medical School in 2000. He trained in Internal Medicine at Mayo Clinic Florida, where he served as Chief Medical Resident. He trained in Nephrology and Clinical Research at Vanderbilt University. After a faculty appointment at Mayo Clinic, he joined the Nephrology Division of Vanderbilt in 2008. In 2022 he joined Utah. Dr. Dwyer is an attending physician and supervises fellows and residents in clinic and inpatient Nephrology services.

    Specialties

    Board Certification

    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Nephrology)

    Patient Rating

    4.9 /5
    ( out of 59 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    June 29, 2025
    UNIVERSITY HOSPITAL

    Appreciated time spent to address my needs.

    January 15, 2025
    UNIVERSITY HOSPITAL

    Very understanding.

    December 19, 2024
    UH HOSPITALS AND CLINICS

    He is one of the best doctors I've ever seen & believe me I've seen a few. He is a huge asset too your facility!!

    December 14, 2024
    UH HOSPITALS AND CLINICS

    Dr Dwyer is a pleasure to talk to and takes a great deal of time to explain my kidney function and disease.

    December 05, 2024
    UH HOSPITALS AND CLINICS

    He is friendly. helpful and experienced. I trust him

    November 06, 2024
    UH HOSPITALS AND CLINICS

    Very good visit with Dr. Dwyer. Highly recommend. He listens and obviously cares about his patients and explains things very well.

    October 30, 2024
    UH HOSPITALS AND CLINICS

    Dr Dwyer is compassionate, clear and professional.

    October 29, 2024
    UH HOSPITALS AND CLINICS

    Dr. Dwyer has been a pleasure to work with. He knows his stuff, and then some.

    October 19, 2024
    UH HOSPITALS AND CLINICS

    Listened and didn't rush

  • Jamie P. Dwyer, M. D. is Assistant Vice-President for Clinical Research at the University of Utah Health in Salt Lake City, UT, USA. He is Professor of Medicine in the Division of Nephrology & Hypertension, and Director of the Utah Data Coordinating Center and the Clinical Research Support Office. He is current Principal Investigator of the Collaborative Study Group (CSG), an international academic research organization dedicated to the exceptionally rigorous design, conduct, analysis, and reporting of large, multi-center clinical trials. He has served on multiple Executive and Steering committees for large trials, particularly in CKD progression and cardiovascular outcomes. In 2015, Dr. Dwyer was appointed as a Consultant to the USA’s Food and Drug Administration’s (FDA) CardioRenal Advisory Committee, and has both served on and defended data before FDA Advisory Committees. In 2017, he and colleagues founded Innovative Renal Care, a health services delivery company dedicated to improving the care of dialysis patients in the United States. In 2023, he and colleagues founded Corventum, Inc.

    Dr. Dwyer is a practicing clinical nephrologist who sees patients across the spectrum of kidney disease. He is an accomplished and highly lauded educator, receiving numerous teaching awards, culminating in his election to Vanderbilt’s Academy for Excellence in Education while faculty there in 2013.

    Dr. Dwyer holds an Sc. B degree in Mathematics and Latin from Brown University in 1996, and an M. D. with Distinction from Brown University Medical School in 2000. He trained in Internal Medicine at Mayo Clinic Florida, where he served as Chief Medical Resident. He trained in Nephrology and Clinical Research at Vanderbilt University. After a faculty appointment at Mayo Clinic, he joined the Nephrology Division of Vanderbilt in 2008. In 2022 he joined Utah. Dr. Dwyer is an attending physician and supervises fellows and residents in clinic and inpatient Nephrology services.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Professor
    Academic Divisions Nephrology & Hypertension
    Board Certification
    American Board of Internal Medicine (Internal Medicine)
    American Board of Internal Medicine (Sub: Nephrology)

    Education history

    Research Fellow Nephrology/Hypertension - Vanderbilt University Research Fellow
    Fellowship Nephrology/Hypertension - Vanderbilt University Clinical Fellow
    Residency Internal Medicine - Mayo Clinic Chief Resident
    Residency Internal Medicine - Mayo Clinic Resident
    Professional Medical Medicine - Brown University School of Medicine M.D. with Distinction
    Undergraduate Classics: Latin - Brown University A.B.
    Undergraduate Mathematics - Brown University Sc.B.

    Selected Publications

    Journal Article

    1. The Blood Pressure Lowering Treatment Trialists Collaboration (In Press). Blood pressure lowering and risk of new-onset type 2 diabetes: an individual-level meta-analysis of 145,000 randomized participants. (Epub ahead of print) Lancet.
    2. Rowan CG, Agiro A, Chan KA, Colman E, White K, Desai P, Dwyer JP (). Hyperkalemia Recurrence Following Medical Nutrition Therapy in Patients with Stage 3–4 Chronic Kidney Disease: The REVOLUTIONIZE I Real-World Study. (Epub ahead of print) Adv Ther (Weinh).
    3. Nissen SE, Wang Q, Nicholls SJ, Zerlasiran, et al (2024). A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial. JAMA.
    4. Cooper M, Cherney DZI, Greene TH, Heerspink HJL, Jardine M, Lewis JB, Wong MG, Baquero E, Heise M, Jochems J, Lanchoney D, Liss C, Reiser D, Scotney P, Velkoska E, Dwyer JP (2024). Vascular Endothelial Growth Factor-B Blockade with CSL346 in Diabetic Kidney Disease: A Phase 2A Randomized Controlled Trial. J Am Soc Nephrol, 35(11), 1546-1557. (Read full article)
    5. Brulotte M, Alvey JS, Casper TC, Cook LJ, Dwyer JP, VanBuren JM (2024). A risk- based approached to source data monitoring and documenting monitoring findings. Contemp Clin Trials Commun.
    6. Brulotte M, Alvey JS, Casper TC, Cook LJ, Dwyer JP, VanBuren JM (2024). A risk-based monitoring approach to source data monitoring and documenting monitoring findings. Contemp Clin Trials, 143, 107581. (Read full article)
    7. Chertow GM, Heerspink HL, Mark PB, Dwyer JP, Nowicki M, Wheeler DC, Correa-Rotter R, Rossing P, Toto RD, Langkilde AM, Jongs N (2024). Effects of Dapagliflozin in Patients with Membranous Nephropathy. Glomerular Dis, 4(1), 137-145. (Read full article)
    8. Rowan CG, Agiro A, Chan KA, Colman E, White K, Desai P, Dwyer JP (2024). Hyperkalemia Recurrence Following Medical Nutrition Therapy in Patients with Stage 3-4 Chronic Kidney Disease: The REVOLUTIONIZE I Real-World Study. Adv Ther, 41(6), 2381-2398. (Read full article)
    9. Heerspink HJL, Greasley PJ, Ahlstrm C, Althage M, Dwyer JP, Law G, Wijkmark E, Lin M, Mercier AK, Sunnker M, Turton M, Wheeler DC, Ambery P (2023). Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial. Nephrol Dial Transplant, 39(3), 414-425. (Read full article)
    10. Drawz PE, Lenoir KM, Rai NK, Rastogi A, Chu CD, Rahbari-Oskoui FF, Whelton PK, Thomas G, McWilliams A, Agarwal AK, Suarez MM, Dobre M, Powell J, Rocco MV, Lash JP, Oparil S, Raj DS, Dwyer JP, Rahman M, Soman S, Townsend RR, Pemu P, Horwitz E, Ix JH, Tuot DS, Ishani A, Pajewski NM (2023). Effect of Intensive Blood Pressure Control on Kidney Outcomes: Long-Term Electronic Health Record-Based Post-Trial Follow-Up of SPRINT. Clin J Am Soc Nephrol, 19(2), 213-223. (Read full article)
    11. Nissen SE, Wolski K, Watts GF, et al (2024). Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a): A Randomized Clinical Trial. JAMA, 18(331), 1534–1543.
    12. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Torne CW, Ryan DH, SELECT Trial Investigators (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. Epub, 389(24), 2221-2232.
    13. Cummins MR, Burr J, Young L, Yeatts SD, Ecklund DJ, Bunnell BE, Dwyer JP, VanBuren JM (2023). Decentralized research technology use in multicenter clinical research studies based at U.S. academic research centers. J Clin Transl Sci, 7(1), e250. (Read full article)
    14. Palm ME, Thompson DD, Edwards T, Swartz K, Herzog KA, Bansal S, Echalier B, DeHart KC, Denmark S, Wilson JL, Nelson S, Waddy SP, Dunsmore SE, Atkinson JC, Wiley K Jr, Hassani S, Dwyer JP, Hanley DF, Dean JM, Ford DE (2023). The Trial Innovation Network Liaison Team: building a national clinical and translational community of practice. J Clin Transl Sci, 7(1), e249. (Read full article)
    15. Dwyer JP, Agiro A, Desai P, Oluwatosin Y (2023). Impact of Sodium Zirconium Cyclosilicate Plus Renin-Angiotensin-Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study. Adv Ther, 40(11), 4777-4791. (Read full article)
    16. Palm ME, Edwards TL, Wieber C, Kay MT, Marion E, Boone L, Nanni A, Jones M, Pham E, Hildreth M, Lane K, McBee N, Benjamin DK Jr, Bernard GR, Dean JM, Dwyer JP, Ford DE, Hanley DF, Harris PA, Wilkins CH, Selker HP (2023). Development, implementation, and dissemination of operational innovations across the trial innovation network. J Clin Transl Sci, 7(1), e251. (Read full article)
    17. Harris PA, Dunsmore SE, Atkinson JC, Benjamin DK Jr, Bernard GR, Dean JM, Dwyer JP, Ford DF, Selker HP, Waddy SP, Wiley KL, Wilkins CH, Cook SK, Burr JS, Edwards TL, Huvane J, Kennedy N, Lane K, Majkowski R, Nelson S, Palm ME, Stroud M, Thompson DD, Busacca L, Elkind MSV, Kimberly RP, Reilly MP, Hanley DF, Trial Innovation Network (2023). Leveraging the Expertise of the CTSA Program to Increase the Impact and Efficiency of Clinical Trials. JAMA Netw Open, 6(10), e2336470. (Read full article)
    18. Moura FA, Berg DD, Bellavia A, Dwyer JP, Mosenzon O, Scirica BM, Wiviott SD, Bhatt DL, Raz I, Feinberg MW, Braunwald E, Morrow DA, Sabatine MS (2023). Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. Diabetes Care, 46(10), 1807-1815. (Read full article)
    19. Agiro A, Dwyer JP, Oluwatosin Y, Desai P (2023). Medical Costs in Patients with Hyperkalemia on Long-Term Sodium Zirconium Cyclosilicate Therapy: The RECOGNIZE II Study. Clinicoecon Outcomes Res, 15, 691-702. (Read full article)
    20. Dwyer JP, Agiro A, Desai P, Cremisi H (2023). Short-term costs in patients with chronic kidney disease treated with dapagliflozin: a retrospective cohort study. Expert Rev Pharmacoecon Outcomes Res, 23(9), 1057-1066. (Read full article)
    21. Chu CD, Lenoir KM, Rai NK, Soman S, Dwyer JP, Rocco MV, Agarwal AK, Beddhu S, Powell JR, Suarez MM, Lash JP, McWilliams A, Whelton PK, Drawz PE, Pajewski NM, Ishani A, Tuot DS (2023). Concordance between clinical outcomes in the Systolic Blood Pressure Intervention Trial and in the electronic health record. Contemp Clin Trials, 128, 107172. (Read full article)
    22. Lane K, Palm M, Marion E, Kay M, Thompson D, Stroud M, Boyle H, Hillery S, Nanni A, Hildreth M, Nelson S, Burr JS, Edwards T, Poole L, Waddy SP, Dunsmore SE, Harris P, Wilkins C, Bernard GB, Dean JM, Dwyer JP, Benjamin Jr, DK, Selker HP, Hanley DF, Ford D (2023). Approaches for enhancing the informativeness and quality of clinical trials: Innovations and principles for implementing multicenter trials from the Trial Innovation Network. J Clin Transl Sci, 7(1), E131.
    23. Moura FA, Berg DD, Bellavia A, Dwyer JP, Mosenzon O, Scirica BM, Wiviott SD, Bhatt DL, Raz I, Feinberg MW, Braunwald E, Morrow DA, Sabatine MS (2023). Risk Assessment of Kidney Disease Progression and Efficacy of SGLT2 Inhibition in Patients With Type 2 Diabetes. Diabetes Care, 46(10), 1-9.
    24. Mosenzon O, Raz I, Wiviott SD, Schechter M, Goodrich EL, Yanuv I, Rozenberg A, Murphy SA, Zelniker TA, Langkilde AM, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Wilding JPH, McGuire DK, Bhatt DL, Leiter LA, Cahn A, Dwyer JP, Heerspink HJL, Sabatine MS (2022). Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial. Diabetes Care, 45(10), 2350-2359. (Read full article)
    25. Canoy D, Copland E, Nazarzadeh M, Ramakrishnan R, Pinho-Gomes AC, Salam A, Dwyer JP, Farzadfar F, Sundstrm J, Woodward M, Davis BR, Rahimi K, Blood Pressure Lowering Treatment Trialists Collaboration, Blood Pressure Lowering Treatment Trialists Collaboration (2022). Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials. Heart, 108(16), 1281-1289. (Read full article)
    26. Drawz PE, Rai NK, Lenoir KM, Suarez M, Powell JR, Raj DS, Beddhu S, Agarwal AK, Soman S, Whelton PK, Lash J, Rahbari-Oskoui FF, Dobre M, Parkulo MA, Rocco MV, McWilliams A, Dwyer JP, Thomas G, Rahman M, Oparil S, Horwitz E, Pajewski NM, Ishani A (2022). Effect of Intensive versus Standard BP Control on AKI and Subsequent Cardiovascular Outcomes and Mortality: Findings from the SPRINT EHR Study. Kidney360, 3(7), 1253-1262. (Read full article)
    27. Heerspink HJL, Cherney D, Postmus D, Stefnsson BV, Chertow GM, Dwyer JP, Greene T, Kosiborod M, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjstrm CD, Toto RD, Wheeler DC, DAPA-CKD Trial Committees and Investigators (2021). A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function. Kidney Int, 101(1), 174-184. (Read full article)
    28. Zuo Y, Cavalcante LB, Smelser JM, Sanghani N, Dwyer JP, Lewis JB, Fogo AB (2021). Anti-Phospholipase A2 Receptor in Nonlupus Patients with Membranous Nephropathy and Crescents. Glomerular Dis, 2(2), 75-82. (Read full article)
    29. The Blood Pressure Lowering Treatment Trialists Collaboration (2021). Age and blood pressure stratified effects of blood pressure- lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual-level meta-analysis of 358,707 randomised participants. Lancet (Edizione Italiana), The, 10305(398), 1053-1064.
    30. The Blood Pressure Lowering Treatment Trialists Collaboration (2021). Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet, 398(10305), 1053-1064.
    31. Cox ZL, Sarrell BA, Cella MK, Tucker B, Arroyo JP, Umanath K, Tidwell W, Guide A, Testani JM, Lewis JB, Dwyer JP (2021). Multinephron Segment Diuretic Therapy to Overcome Diuretic Resistance in Acute Heart Failure: A Single-Center Experience. J Card Fail. (Read full article)
    32. Mosenzon O, Wiviott SD, Heerspink HJL, Dwyer JP, Cahn A, Goodrich EL, Rozenberg A, Schechter M, Yanuv I, Murphy SA, Zelniker TA, Gause-Nilsson IAM, Langkilde AM, Fredriksson M, Johansson PA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Raz I (2021). The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. Diabetes Care, 44(8), 1805-1815. (Read full article)
    33. Zelniker TA, Raz I, Mosenzon O, Dwyer JP, Heerspink HHJL, Cahn A, Goodrich EL, Im K, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson I, Langkilde AM, Sabatine MS, Wiviott SD (2022). Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol, 6(7), 801-810. (Read full article)
    34. SPRINT Research Group, Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, Cutler JA, Evans GW, Johnson KC, Kitzman DW, Oparil S, Rahman M, Reboussin DM, Rocco MV, Sink KM, Snyder JK, Whelton PK, Williamson JD, Wright JT Jr, Ambrosius WT (2021). Final Report of a Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med, 384(20), 1921-1930. (Read full article)
    35. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Inzucchi SE, Kosiborod MN, Cherney DZI, Dwyer JP, Scirica BM, Bailey CJ, Daz R, Ray KK, Udell JA, Lopes RD, Lapuerta P, Steg PG, SCORED Investigators (2020). Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med, 384(2), 129-139. (Read full article)
    36. Drawz PE, Agarwal A, Dwyer JP, Horwitz E, Lash J, Lenoir K, McWilliams A, Oparil S, Rahbari-Oskoui F, Rahman M, Parkulo MA, Pemu P, Raj DS, Rocco M, Soman S, Thomas G, Tuot DS, Whelton PK, Pajewski NM (2020). Concordance Between Blood Pressure in the Systolic Blood Pressure Intervention Trial and in Routine Clinical Practice. JAMA Intern Med, 180(12), 1655-1663. (Read full article)
    37. Heerspink HJL, Stefnsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjstrm CD, Toto RD, Langkilde AM, Wheeler DC, DAPA-CKD Trial Committees and Investigators (2020). Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med, 383(15), 1436-1446. (Read full article)
    38. Wheeler DC, Stefansson BV, Batiushin M, Bilchenko O, Cherney DZI, Chertow GM, Douthat W, Dwyer JP, Escudero E, Pecoits-Filho R, Furuland H, Grriz JL, Greene T, Haller H, Hou FF, Kang SW, Isidto R, Khullar D, Mark PB, McMurray JJV, Kashihara N, Nowicki M, Persson F, Correa-Rotter R, Rossing P, Toto RD, Umanath K, Van Bui P, Wittmann I, Lindberg M, Sjstrm CD, Langkilde AM, Heerspink HJL (2020). The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics. Nephrol Dial Transplant, 35(10), 1700-1711. (Read full article)
    39. Burgner A, Ikizler TA, Dwyer JP (2020). COVID-19 and the Inpatient Dialysis Unit: Managing Resources during Contingency Planning Pre-Crisis. Clin J Am Soc Nephrol, 15(5), 720-722. (Read full article)
    40. Heerspink HJL, Stefansson BV, Chertow GM, Correa-Rotter R, Greene T, Hou FF, Lindberg M, McMurray J, Rossing P, Toto R, Langkilde AM, Wheeler DC, DAPA-CKD Investigators (2019). Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant, 35(2), 274-282. (Read full article)
    41. Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA, Heerspink HJL, Zelniker TA, Dwyer JP, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Kato ET, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, Raz I (2019). Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol, 7(8), 606-617. (Read full article)
    42. Beddhu S, Shen J, Cheung AK, Kimmel PL, Chertow GM, Wei G, Boucher RE, Chonchol M, Arman F, Campbell RC, Contreras G, Dwyer JP, Freedman BI, Ix JH, Kirchner K, Papademetriou V, Pisoni R, Rocco MV, Whelton PK, Greene T (2019). Implications of Early Decline in eGFR due to Intensive BP Control for Cardiovascular Outcomes in SPRINT. J Am Soc Nephrol, 30(8), 1523-1533. (Read full article)
    43. Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Bonaca MP, Ruff CT, Desai AS, Goto S, Johansson PA, Gause-Nilsson I, Johanson P, Langkilde AM, Raz I, Sabatine MS, Wiviott SD (2019). Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. Circulation, 139(22), 2528-2536. (Read full article)
    44. Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Nicolau JC, Gause-Nilsson IAM, Fredriksson M, Langkilde AM, Sabatine MS, Wiviott SD (2019). Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. Circulation, 139(22), 2516-2527. (Read full article)
    45. Rahimi K, Canoy D, Nazarzadeh M, Salimi-Khorshidi G, Woodward M, Teo K, Davis BR, Chalmers J, Pepine CJ, The Blood Pressure Lowering Treatment Trialists Collaboration (2019). Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC). BMJ Open, 9(5), e028698. (Read full article)
    46. Waguespack DR, Dwyer JP (2018). Assessment of Blood Pressure: Techniques and Implications From Clinical Trials. Adv Chronic Kidney Dis, 26(2), 87-91. (Read full article)
    47. Wagenlehner FME, Cloutier DJ, Komirenko AS, Cebrik DS, Krause KM, Keepers TR, Connolly LE, Miller LG, Friedland I, Dwyer JP, EPIC Study Group (2019). Once-Daily Plazomicin for Complicated Urinary Tract Infections. N Engl J Med, 380(8), 729-740. (Read full article)
    48. Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, Chan TM, Hou FF, Lewis JB, Locatelli F, Praga M, Schena FP, Levey AS, Inker LA, Chronic Kidney Disease Epidemiology Collaboration (2019). Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol, 7(2), 128-139. (Read full article)
    49. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS, DECLARETIMI 58 Investigators (2018). Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med, 380(4), 347-357. (Read full article)
    50. Scirica BM, Bohula EA, Dwyer JP, Qamar A, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Murphy SA, Im K, Leiter LA, Gupta M, Patel T, Miao W, Perdomo C, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD, CAMELLIA-TIMI 61 Steering Committee and Investigators (2018). Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Circulation, 139(3), 366-375. (Read full article)
    51. Bohula EA, Scirica BM, Inzucchi SE, McGuire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Dwyer JP, Corbalan R, Hamm C, Kaplan L, Nicolau JC, Ophuis TO, Ray KK, Ruda M, Spinar J, Patel T, Miao W, Perdomo C, Francis B, Dhadda S, Bonaca MP, Ruff CT, Sabatine MS, Wiviott SD, CAMELLIA-TIMI 61 Steering Committee Investigators (2018). Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet, 392(10161), 2269-2279. (Read full article)
    52. Nogid B, Lacy MK, Jacobs M, Bruss J, Dwyer J (2018). Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials. Pharmacotherapy, 38(10), 990-998. (Read full article)
    53. Supiano MA, Lovato L, Ambrosius WT, Bates J, Beddhu S, Drawz P, Dwyer JP, Hamburg NM, Kitzman D, Lash J, Lustigova E, Miracle CM, Oparil S, Raj DS, Weiner DE, Taylor A, Vita JA, Yunis R, Chertow GM, Chonchol M (2018). Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants. PLoS One, 13(9), e0203305. (Read full article)
    54. Bohula EA, Wiviott SD, McGuire DK, Inzucchi SE, Kuder J, Im K, Fanola CL, Qamar A, Brown C, Budaj A, Garcia-Castillo A, Gupta M, Leiter LA, Weissman NJ, White HD, Patel T, Francis B, Miao W, Perdomo C, Dhadda S, Bonaca MP, Ruff CT, Keech AC, Smith SR, Sabatine MS, Scirica BM, CAMELLIA-TIMI 61 Steering Committee and Investigators (2018). Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. N Engl J Med, 379(12), 1107-1117. (Read full article)
    55. Shapiro BP, Ambrosius WT, Blackshear JL, Cushman WC, Whelton PK, Oparil S, Beddhu S, Dwyer JP, Gren LH, Kostis WJ, Lioudis M, Pisoni R, Rosendorff C, Haley WE, SPRINT Research Group (2018). Impact of Intensive Versus Standard Blood Pressure Management by Tertiles of Blood Pressure in SPRINT (Systolic Blood Pressure Intervention Trial). Hypertension, 71(6), 1064-1074. (Read full article)
    56. Toth PP, Dwyer JP, Cannon CP, Colhoun HM, Rader DJ, Upadhyay A, Louie MJ, Koren A, Letierce A, Mandel J, Banach M (2018). Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int, 93(6), 1397-1408. (Read full article)
    57. Rocco MV, Sink KM, Lovato LC, Wolfgram DF, Wiegmann TB, Wall BM, Umanath K, Rahbari-Oskoui F, Porter AC, Pisoni R, Lewis CE, Lewis JB, Lash JP, Katz LA, Hawfield AT, Haley WE, Freedman BI, Dwyer JP, Drawz PE, Dobre M, Cheung AK, Campbell RC, Bhatt U, Beddhu S, Kimmel PL, Reboussin DM, Chertow GM, SPRINT Research Group (2017). Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis, 71(3), 352-361. (Read full article)
    58. Weldegiorgis M, de Zeeuw D, Dwyer JP, Mol P, Heerspink HJL (2017). Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects? Clin J Am Soc Nephrol, 12(10), 1595-1600. (Read full article)
    59. Berlowitz DR, Foy CG, Kazis LE, Bolin LP, Conroy MB, Fitzpatrick P, Gure TR, Kimmel PL, Kirchner K, Morisky DE, Newman J, Olney C, Oparil S, Pajewski NM, Powell J, Ramsey T, Simmons DL, Snyder J, Supiano MA, Weiner DE, Whittle J, SPRINT Research Group (2017). Effect of Intensive Blood-Pressure Treatment on Patient-Reported Outcomes. N Engl J Med, 377(8), 733-744. (Read full article)
    60. Vincenti F, Fervenza FC, Campbell KN, Diaz M, Gesualdo L, Nelson P, Praga M, Radhakrishnan J, Sellin L, Singh A, Thornley-Brown D, Veronese FV, Accomando B, Engstrand S, Ledbetter S, Lin J, Neylan J, Tumlin J, Focal Segmental Glomerulosclerosis Study Group (2017). A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis. Kidney Int Rep, 2(5), 800-810. (Read full article)
    61. Jalal D, McFadden M, Dwyer JP, Umanath K, Aguilar E, Yagil Y, Greco B, Sika M, Lewis JB, Greene T, Goral S (2016). Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis. Hemodial Int, 21(2), 243-249. (Read full article)
    62. Umanath K, Greco B, Jalal DI, McFadden M, Sika M, Koury MJ, Niecestro R, Hunsicker LG, Greene T, Lewis JB, Dwyer JP (2017). The safety of achieved iron stores and their effect on IV iron and ESA use: post-hoc results from a randomized trial of ferric citrate as a phosphate binder in dialysis
. Clin Nephrol, 87 (2017)(3), 124-133. (Read full article)
    63. Drawz PE, Pajewski NM, Bates JT, Bello NA, Cushman WC, Dwyer JP, Fine LJ, Goff DC Jr, Haley WE, Krousel-Wood M, McWilliams A, Rifkin DE, Slinin Y, Taylor A, Townsend R, Wall B, Wright JT, Rahman M (2016). Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure: Results From the SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory Blood Pressure Study. Hypertension, 69(1), 42-50. (Read full article)
    64. van der Sande NG, Dorresteijn JA, Visseren FL, Dwyer JP, Blankestijn PJ, van der Graaf Y, Heerspink HL (2016). Individualized prediction of the effect of angiotensin receptor blockade on renal and cardiovascular outcomes in patients with diabetic nephropathy. Diabetes Obes Metab, 18(11), 1120-1127. (Read full article)
    65. Dwyer JP (2016). We Give Too Much Intravenous Iron. Semin Dial, 29(4), 309-11. (Read full article)
    66. Tamura MK, Pajewski NM, Bryan RN, Weiner DE, Diamond M, Van Buren P, Taylor A, Beddhu S, Rosendorff C, Jahanian H, Zaharchuk G, SPRINT Study Research Group (2016). Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults. Neurology, 86(13), 1208-16. (Read full article)
    67. Chang TI, Evans G, Cheung AK, Cushman WC, Diamond MJ, Dwyer JP, Huan Y, Kitzman D, Kostis JB, Oparil S, Rastogi A, Roumie CL, Sahay R, Stafford RS, Taylor AA, Wright JT Jr, Chertow GM, SPRINT Study Research Group (2016). Patterns and Correlates of Baseline Thiazide-Type Diuretic Prescription in the Systolic Blood Pressure Intervention Trial. Hypertension, 67(3), 550-5. (Read full article)
    68. Schievink B, Krpelin T, Mulder S, Parving HH, Remuzzi G, Dwyer J, Vemer P, de Zeeuw D, Lambers Heerspink HJ (2015). Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. Diabetes Obes Metab, 18(1), 64-71. (Read full article)
    69. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT (2015). A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med, 373(22), 2103-16. (Read full article)
    70. Umanath K, Jalal DI, Greco BA, Umeukeje EM, Reisin E, Manley J, Zeig S, Negoi DG, Hiremath AN, Blumenthal SS, Sika M, Niecestro R, Koury MJ, Ma KN, Greene T, Lewis JB, Dwyer JP, Collaborative Study Group (2015). Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. J Am Soc Nephrol, 26(10), 2578-87. (Read full article)
    71. Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, Umanath K, Abraham JD, Arfeen SS, Bowline IG, Chernin G, Fadem SZ, Goral S, Koury M, Sinsakul MV, Weiner DE, Collaborative Study Group (2015). The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. Am J Kidney Dis, 66(3), 479-88. (Read full article)
    72. Rodby RA, Umanath K, Niecestro R, Bond TC, Sika M, Lewis J, Dwyer JP, Collaborative Study Group (2015). Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data. Drugs R D, 15(3), 271-9. (Read full article)
    73. Rodby R, Umanath K, Niecestro R, Jackson JH, Sika M, Lewis JB, Dwyer JP, Collaborative Study Group (2014). Phosphorus binding with ferric citrate is associated with fewer hospitalizations and reduced hospitalization costs. Expert Rev Pharmacoecon Outcomes Res, 15(3), 545-50. (Read full article)
    74. Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT, Whittier FC, Linfert DR, Galphin CM, Athreya BP, Nossuli AK, Chang IJ, Blumenthal SS, Manley J, Zeig S, Kant KS, Olivero JJ, Greene T, Dwyer JP, Collaborative Study Group (2014). Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol, 26(2), 493-503. (Read full article)
    75. Coffin ST, Waguespack DR, Haglund NA, Maltais S, Dwyer JP, Keebler ME (2015). Kidney dysfunction and left ventricular assist device support: a comprehensive perioperative review. Cardiorenal Med, 5(1), 48-60. (Read full article)
    76. Dwyer JP, Greco BA, Umanath K, Packham D, Fox JW, Peterson R, Broome BR, Greene LE, Sika M, Lewis JB (2014). Pyridoxamine dihydrochloride in diabetic nephropathy (PIONEER-CSG-17): lessons learned from a pilot study. Nephron, 129(1), 22-8. (Read full article)
    77. McMullan CJ, Lambers Heerspink HJ, Parving HH, Dwyer JP, Forman JP, de Zeeuw D (2014). Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. Am J Kidney Dis, 64(5), 714-22. (Read full article)
    78. Sinsakul M, Rodby R, Umanath K, Niecestro R, Dwyer JP (2014). Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data. Expert Rev Clin Pharmacol, 7(6), 705-10. (Read full article)
    79. Ambrosius WT, Sink KM, Foy CG, Berlowitz DR, Cheung AK, Cushman WC, Fine LJ, Goff DC Jr, Johnson KC, Killeen AA, Lewis CE, Oparil S, Reboussin DM, Rocco MV, Snyder JK, Williamson JD, Wright JT Jr, Whelton PK, SPRINT Study Research Group (2014). The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT). Clin Trials, 11(5), 532-46. (Read full article)
    80. Haglund NA, Feurer ID, Dwyer JP, Stulak JM, DiSalvo TG, Keebler ME, Schlendorf KH, Wigger MA, Maltais S (2014). Does renal dysfunction and method of bridging support influence heart transplant graft survival? Ann Thorac Surg, 98(3), 835-41. (Read full article)
    81. Umanath K, Lewis JB, Dwyer JP (2013). Optimizing blood pressure control in patients with nondiabetic glomerular disease. Adv Chronic Kidney Dis, 21(2), 200-4. (Read full article)
    82. Lambers Heerspink HJ, Weldegiorgis M, Inker LA, Gansevoort R, Parving HH, Dwyer JP, Mondal H, Coresh J, Greene T, Levey AS, de Zeeuw D (2013). Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). Am J Kidney Dis, 63(2), 244-50. (Read full article)
    83. Hartle PM, Carlo ME, Dwyer JP, Fogo AB (2013). AKI in an HIV patient. J Am Soc Nephrol, 24(8), 1204-8. (Read full article)
    84. Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, Kaplan M, Zeig S, Koury MJ, Blumenthal SS, Lewis JB, Collaborative Study Group (2013). Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis, 61(5), 759-66. (Read full article)
    85. Umanath K, Sika M, Niecestro R, Connelly C, Schulman G, Koury MJ, Lewis JB, Dwyer JP, Collaborative Study Group (2012). Rationale and study design of a three-period, 58-week trial of ferric citrate as a phosphate binder in patients with ESRD on dialysis. Hemodial Int, 17(1), 67-74. (Read full article)
    86. Umanath K, Morrison RS, Christopher Wilbeck J, Schulman G, Bream P, Dwyer JP (2012). In-center thrombolysis for clotted AV access: a cohort review. Semin Dial, 26(1), 124-9. (Read full article)
    87. Elliott MR, Soto Soto JM, Haley WE, Fitzpatrick PM, Dwyer JP (2012). Labile hypertension: characteristics of a referred cohort. Clin Exp Hypertens, 35(3), 207-12. (Read full article)
    88. Dwyer JP, Lewis JB (2012). Nonproteinuric diabetic nephropathy: when diabetics don't read the textbook. Med Clin North Am, 97(1), 53-8. (Read full article)
    89. Umanath K, Niecestro R, Lewis JB, Dwyer JP (2019). Ferric citrate: a novel phosphate-binding agent. Expert Rev Endocrinol Metab, 8(1), 13-19. (Read full article)
    90. Fatima H, Siew ED, Dwyer JP, Paueksakon P (2012). Membranous glomerulopathy with superimposed pauci-immune necrotizing crescentic glomerulonephritis. Clin Kidney J, 5(6), 587-90. (Read full article)
    91. Siew ED, Ikizler TA, Matheny ME, Shi Y, Schildcrout JS, Danciu I, Dwyer JP, Srichai M, Hung AM, Smith JP, Peterson JF (2012). Estimating baseline kidney function in hospitalized patients with impaired kidney function. Clin J Am Soc Nephrol, 7(5), 712-9. (Read full article)
    92. Dwyer JP, Parving HH, Hunsicker LG, Ravid M, Remuzzi G, Lewis JB (2011). Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study. Cardiorenal Med, 2(1), 1-10. (Read full article)
    93. Packham DK, Wolfe R, Reutens AT, Berl T, Heerspink HL, Rohde R, Ivory S, Lewis J, Raz I, Wiegmann TB, Chan JC, de Zeeuw D, Lewis EJ, Atkins RC, Collaborative Study Group (2011). Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol, 23(1), 123-30. (Read full article)
    94. Lewis EJ, Greene T, Spitalewiz S, Blumenthal S, Berl T, Hunsicker LG, Pohl MA, Rohde RD, Raz I, Yerushalmy Y, Yagil Y, Herskovits T, Atkins RC, Reutens AT, Packham DK, Lewis JB, Collaborative Study Group (2011). Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol, 23(1), 131-6. (Read full article)
    95. Sinsakul M, Sika M, Koury M, Shapiro W, Greene T, Dwyer J, Smith M, Korbet S, Lewis J, Collaborative Study Group (2012). The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract, 121(1-2), c25-9. (Read full article)
    96. Packham DK, Alves TP, Dwyer JP, Atkins R, de Zeeuw D, Cooper M, Shahinfar S, Lewis JB, Lambers Heerspink HJ (2011). Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. Am J Kidney Dis, 59(1), 75-83. (Read full article)
    97. Lewis EJ, Lewis JB, Greene T, Hunsicker LG, Berl T, Pohl MA, de Zeeuw D, Heerspink HL, Rohde RD, Atkins RC, Reutens AT, Packham DK, Raz I, Collaborative Study Group (2011). Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis, 58(5), 729-36. (Read full article)
    98. Dwyer JP, Lewis JB (2011). Olmesartan to prevent the development of microalbuminuria: is it new? Is it true? Is it important? Am J Kidney Dis, 58(5), 700-3. (Read full article)
    99. Basford AW, Lewis J, Dwyer JP, Fogo AB (2011). Membranous nephropathy with crescents. J Am Soc Nephrol, 22(10), 1804-8. (Read full article)
    100. Packham DK, Ivory SE, Reutens AT, Wolfe R, Rohde R, Lambers Heerspink H, Dwyer JP, Atkins RC, Lewis J, Collaborative Study Group (2011). Proteinuria in type 2 diabetic patients with renal impairment: the changing face of diabetic nephropathy. Nephron Clin Pract, 118(4), c331-8. (Read full article)
    101. Elliott MR, Cortese C, Moreno-Aspitia A, Dwyer JP (2009). Plasma cell dyscrasia causing light chain tubulopathy without Fanconi syndrome. Am J Kidney Dis, 55(6), 1136-41. (Read full article)
    102. Dwyer JP, Greco BA, Lewis JB (2009). Evaluation of renal artery stenosis in dialysis patients. Semin Dial, 22(5), 519-23. (Read full article)
    103. Bridges MD, St Amant BS, McNeil RB, Cernigliaro JG, Dwyer JP, Fitzpatrick PM (2009). High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: Prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function. AJR Am J Roentgenol, 192(6), 1538-43. (Read full article)
    104. Irizarry-Alvarado JM, Dwyer JP, Brumble LM, Alvarez S, Mendez JC (2009). Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases. AIDS Read, 19(3), 114-21. (Read full article)
    105. Umana IE, Dwyer JP (2009). Vicarious contrast excretion by the gallbladder in contrast nephropathy. Kidney Int, 75(4), 446. (Read full article)
    106. Lette F, Dwyer JP (2008). The fluid craze. Lancet, 372(9641), 782-4. (Read full article)
    107. Dwyer JP, Yates KM, Sumner EL, Stone WJ, Wang Y, Koury MJ, Fogo AB, Zent R (2007). Chronic myeloid leukemia-associated membranoproliferative glomerulonephritis that responded to imatinib mesylate therapy. Clin Nephrol, 67(3), 176-81. (Read full article)

    Review

    1. Dwyer JP, Kelepouris E (2022). New Directions in Phosphorus Management in Dialysis. [Review]. J Ren Nutr, 33(1), 12-16. (Read full article)
    2. Heyman SN, Raz I, Dwyer JP, Weinberg Sibony R, Lewis JB, Abassi Z (2022). Diabetic Proteinuria Revisited: Updated Physiologic Perspectives. [Review]. Cells, 11(18). (Read full article)

    Book Chapter

    1. Huston HK, Dwyer JP (2018). Advances in the Management of Hyperkalemia. In Fadem SZ (Ed.), Essentials of Chronic Kidney Disease (2nd Edition).

    Conference Proceedings

    1. Eckardt KU, Bansal N, Coresh J, Evans M, Grams ME, Herzog CA, James MT, Heerspink HJL, Pollock CA, Stevens PE, Tamura MK, Tonelli MA, Wheeler DC, Winkelmayer WC, Cheung M, Hemmelgarn BR, Conference Participants (2018). Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int, United States, 93(6), 1281-1292. (Read full article)

    Editorial

    1. Umanath K, Burgner A, Lewis JB, Dwyer JP (2014). Guidelines and Straitjackets: blood pressure targets in the era of the Eighth Joint National Committee. Am J Kidney Dis, 63(6), 895-9. (Read full article)

    Letter

    1. McKinnell JA, Dwyer JP, Talbot GH, Connolly LE, Friedland I, Smith A, Jubb AM, Serio AW, Krause KM, Daikos GL, CARE Study Group (2019). Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae. [Letter to the editor]. N Engl J Med, 380(8), 791-793. (Read full article)
    2. Choma DP, Cavanaugh KL, Dwyer JP (2010). Is it always wrong to perform futile CPR? [Letter to the editor]. N Engl J Med, 362(21), 2036; author reply 2036-7. (Read full article)
    3. Dwyer JP, Cohen MD (2005). Interns' work hours. [Letter to the editor]. N Engl J Med, 352(7), 726-8; author reply 726-8. (Read full article)